Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1971 1
1972 1
1973 1
1974 1
1975 4
1976 4
1977 2
1978 4
1979 2
1980 3
1981 3
1982 5
1983 6
1984 2
1985 1
1986 3
1987 3
1988 5
1989 7
1990 9
1991 4
1992 10
1993 13
1994 10
1995 3
1996 5
1997 3
1998 9
1999 8
2000 14
2001 7
2002 9
2003 8
2004 4
2005 4
2006 4
2007 6
2008 6
2009 5
2010 6
2011 5
2012 4
2013 11
2014 10
2015 12
2016 14
2017 14
2018 7
2019 11
2020 12
2021 6
2022 2
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.
Lynggaard LS, Rank CU, Als-Nielsen B, Hoejfeldt SG, Heyman M, Schmiegelow K, Albertsen BK. Lynggaard LS, et al. Cochrane Database Syst Rev. 2023 May 31;5(5):CD014570. doi: 10.1002/14651858.CD014570.pub2. Cochrane Database Syst Rev. 2023. PMID: 37260073
Currently, polyethylene glycolated native Escherichia coli-derived L-asparaginase (PEG-asparaginase) is the preferred first-line asparaginase preparation. ...In two studies, we found that a higher number of PEG-asparaginase doses probably increases pan …
Currently, polyethylene glycolated native Escherichia coli-derived L-asparaginase (PEG-asparaginase) is the preferred first-li …
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.
Wang X, Zhang L, Liu X, Li X, Li L, Fu X, Sun Z, Wu J, Zhang X, Yan J, Chang Y, Nan F, Zhou Z, Wu X, Tian L, Ma M, Li Z, Yu H, Zhu L, Wang Y, Shi C, Feng X, Li J, Ding M, Zhang J, Dong M, Xue H, Wang J, Zou L, Su L, Wu J, Liu L, Bao H, Zhang L, Guo Y, Guo S, Lu Y, Young KH, Li W, Zhang M. Wang X, et al. JAMA Oncol. 2022 Jul 1;8(7):1035-1041. doi: 10.1001/jamaoncol.2022.1968. JAMA Oncol. 2022. PMID: 35708709 Free PMC article. Clinical Trial.
IMPORTANCE: The L-asparaginase-based SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemotherapy regimen has shown higher response rates and survival benefit over an anthracycline-containing regimen. ...
IMPORTANCE: The L-asparaginase-based SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide) chemothera …
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Sato A, et al. Lancet Haematol. 2023 Jun;10(6):e419-e432. doi: 10.1016/S2352-3026(23)00072-8. Epub 2023 May 8. Lancet Haematol. 2023. PMID: 37167992 Clinical Trial.
This trial aimed to reduce the rate of radiation and haematopoietic stem-cell transplantation (HSCT) while improving outcomes by adding nelarabine, intensified L-asparaginase, and protracted intrathecal therapy in the Berlin-Frankfurt-Munster (BFM)-type treatment. ...All p …
This trial aimed to reduce the rate of radiation and haematopoietic stem-cell transplantation (HSCT) while improving outcomes by adding nela …
L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis.
Pokrovsky VS, Vinnikov D. Pokrovsky VS, et al. Expert Rev Anticancer Ther. 2017 Aug;17(8):759-768. doi: 10.1080/14737140.2017.1344100. Epub 2017 Jun 21. Expert Rev Anticancer Ther. 2017. PMID: 28621166 Review.
OBJECTIVES: The aim of this review was to compare the efficacy of asparaginase (ASP)-containing vs ASP-absent regimens in the first-line treatment of ENKTL patients. ...
OBJECTIVES: The aim of this review was to compare the efficacy of asparaginase (ASP)-containing vs ASP-absent regimens in the first-l …
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC, Liu Y, Bottiglieri T, Arning E, Cheng C, Karol SE, Yang JJ, Zhou Y, Inaba H, Pui CH, Jeha S, Relling MV. Panetta JC, et al. Cancer Chemother Pharmacol. 2021 Oct;88(4):655-664. doi: 10.1007/s00280-021-04315-0. Epub 2021 Jun 25. Cancer Chemother Pharmacol. 2021. PMID: 34170389 Free PMC article. Clinical Trial.
PURPOSE: We evaluated effects of asparaginase dosage, schedule, and formulation on CSF asparagine in children with acute lymphoblastic leukemia (ALL). ...The median (quartile range) serum asparaginase activity needed to maintain CSF asparagine below 1 M was 0.44 (0. …
PURPOSE: We evaluated effects of asparaginase dosage, schedule, and formulation on CSF asparagine in children with acute lymphoblasti …
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP. Dunsmore KP, et al. J Clin Oncol. 2020 Oct 1;38(28):3282-3293. doi: 10.1200/JCO.20.00256. Epub 2020 Aug 19. J Clin Oncol. 2020. PMID: 32813610 Free PMC article. Clinical Trial.
Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
Hayashi RJ, Winter SS, Dunsmore KP, Devidas M, Chen Z, Wood BL, Hermiston ML, Teachey DT, Perkins SL, Miles RR, Raetz EA, Loh ML, Winick NJ, Carroll WL, Hunger SP, Lim MS, Gross TG, Bollard CM. Hayashi RJ, et al. J Clin Oncol. 2020 Sep 10;38(26):3062-3070. doi: 10.1200/JCO.20.00531. Epub 2020 Jun 17. J Clin Oncol. 2020. PMID: 32552472 Free PMC article. Clinical Trial.
Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4().
Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL. Schore RJ, et al. Leuk Lymphoma. 2019 Jul;60(7):1740-1748. doi: 10.1080/10428194.2018.1542146. Epub 2019 Jan 10. Leuk Lymphoma. 2019. PMID: 30626253 Free PMC article. Clinical Trial.
The target level of plasma asparaginase activity to achieve asparagine depletion has been between 0.05 and 0.4 IU/mL. ...Matched plasma asparaginase/asparagine levels of the clearance of 54 doses of pegaspargase given in induction or consolidation demonstrated that …
The target level of plasma asparaginase activity to achieve asparagine depletion has been between 0.05 and 0.4 IU/mL. ...Matched plas …
Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.
Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL. Maury S, et al. N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085. N Engl J Med. 2016. PMID: 27626518 Free article. Clinical Trial.
The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to asparaginase were observed in the rituximab group. CONCLUSIONS: Adding rituximab to the ALL chemotherapy protocol improved the outcome f …
The overall incidence rate of severe adverse events did not differ significantly between the two groups, but fewer allergic reactions to …
Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
Hasan H, Shaikh OM, Rassekh SR, Howard AF, Goddard K. Hasan H, et al. Pediatr Blood Cancer. 2017 Jan;64(1):81-88. doi: 10.1002/pbc.26200. Epub 2016 Aug 31. Pediatr Blood Cancer. 2017. PMID: 27578304 Review.
BACKGROUND: Pegylated-asparaginase (PEG-ASP) is a critical treatment for pediatric acute lymphoblastic leukemia (ALL) and has traditionally been delivered via intramuscular (IM) injection. ...
BACKGROUND: Pegylated-asparaginase (PEG-ASP) is a critical treatment for pediatric acute lymphoblastic leukemia (ALL) and has traditi …
299 results